Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · September 05, 2021

Spartalizumab Versus Chemotherapy in Patients With Recurrent/Metastatic Nasopharyngeal Cancer

Clinical Cancer Research


Additional Info

Clinical Cancer Research
Phase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, Versus Chemotherapy in Patients With Recurrent/Metastatic Nasopharyngeal Cancer
Clin. Cancer Res 2021 Aug 25;[EPub Ahead of Print], C Even, HM Wang, SH Li, RK Ngan, A Dechaphunkul, L Zhang, CJ Yen, PC Chan, S Chakrabandhu, BBY Ma, S Tanasanvimon, VHF Lee, PJ Lou, Z Li, AI Spira, A Sukari, J Guigay, S McCune, J Gonzalez-Maffe, S Szpakowski, Y Yao, H Liang, J Mataraza, R Séchaud, L Manenti, DW Lim

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading